Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Pharma-Bio Serv (PBSV) over the last 17 years, with Q4 2025 value amounting to $350.0.

  • Pharma-Bio Serv's Capital Expenditures fell 9977.71% to $350.0 in Q4 2025 from the same period last year, while for Oct 2025 it was $6644.0, marking a year-over-year decrease of 9584.08%. This contributed to the annual value of $6644.0 for FY2025, which is 9584.08% down from last year.
  • According to the latest figures from Q4 2025, Pharma-Bio Serv's Capital Expenditures is $350.0, which was down 9977.71% from $2036.0 recorded in Q3 2025.
  • Pharma-Bio Serv's Capital Expenditures' 5-year high stood at $157015.0 during Q4 2024, with a 5-year trough of -$1580.0 in Q4 2023.
  • Over the past 5 years, Pharma-Bio Serv's median Capital Expenditures value was $2087.0 (recorded in 2022), while the average stood at $12300.5.
  • As far as peak fluctuations go, Pharma-Bio Serv's Capital Expenditures plummeted by 11393.77% in 2021, and later skyrocketed by 1003765.82% in 2024.
  • Over the past 5 years, Pharma-Bio Serv's Capital Expenditures (Quarter) stood at -$881.0 in 2021, then skyrocketed by 1477.64% to $12137.0 in 2022, then plummeted by 113.02% to -$1580.0 in 2023, then soared by 10037.66% to $157015.0 in 2024, then crashed by 99.78% to $350.0 in 2025.
  • Its Capital Expenditures stands at $350.0 for Q4 2025, versus $2036.0 for Q3 2025 and $4258.0 for Q2 2025.